Skydance Corp: Form 10-Q for the period ended Jun 30, 2026
Filed with the SEC on Aug 4, 2026 and accepted by EDGAR at Aug 4, 2026, 17:17 ET.
Controls and procedures
As filed, 669 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our principal executive officer and principal financial officer have concluded that, as of the end of the period
covered by this report, our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the
Securities Exchange Act of 1934, as amended) were effective, based on the evaluation of these controls and
procedures required by Rule 13a-15(b) or 15d-15(b) of the Securities Exchange Act of 1934, as amended.
No change in our internal control over financial reporting occurred during our last fiscal quarter that has materially
affected, or is reasonably likely to materially affect, our internal control over financial reporting.
-89-
Risk factors
As filed, 14,713 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2025
(filed with the Securities and Exchange Commission on February 25, 2026), the following risks relating to the
WBD Merger could adversely affect our business, financial condition or results of operations before and after the
completion of the WBD Merger.
Risks Relating to the WBD Merger
The proposed WBD Merger may cause disruption in our and WBD’s business and commercial relationships.
The proposed WBD Merger could cause disruptions to our business or commercial relationships, or those of WBD,
which could have an adverse impact on our and WBD’s business, financial condition or results of operations.
Parties with which we or WBD have business relationships may experience uncertainty as to the future of such
relationships and may delay or defer certain business decisions, seek alternative relationships with third parties or
seek to alter their present business relationships with us. Parties with whom we or WBD otherwise may have
sought to establish business relationships may seek alternative relationships with third parties. We have
experienced, and may continue to experience, negative publicity relating to the WBD Merger, which could have an
adverse effect on our or WBD’s ongoing operations including, but not limited to, retaining and attracting
employees and creative talent, maintaining our relationships with existing customers and obtaining potential new
customers. We compete with other content creators for creative talent, including producers, directors, actors and
writers and if we fail to retain or attract new key employees or creative talent, our business, financial condition or
results of operations could be adversely affected.
The pursuit of the WBD Merger and the preparation for the integration of WBD may place a significant burden on
our management and internal resources. The diversion of management’s attention away from day-to-day business
concerns and any difficulties encountered in the transition and integration process could adversely affect our
business, financial condition or results of operations.
Failure to consummate the WBD Merger could negatively impact our business, financial condition, results of
operations and stock price.
The WBD Merger cannot be consummated until conditions to Closing (as defined in the WBD Merger Agreement)
are satisfied or, if permissible under applicable law, waived. The WBD Merger is subject to numerous Closing
conditions, including the receipt of required regulatory approvals and the absence of any orders enjoining the
consummation of the WBD Merger. See “—The WBD Merger is subject to a number of Closing conditions and, if
these conditions are not satisfied, the WBD Merger Agreement may be terminated in accordance with its terms and
the WBD Merger may not be consummated. In addition, the parties have the right to terminate the WBD Merger
Agreement under certain circumstances, in which case the WBD Merger would not be consummated.”
There can be no assurance that the conditions to completion of the WBD Merger, including the receipt of required
regulatory approvals, will be satisfied or waived on a timely basis or at all. Further, there can be no assurance that
governmental authorities will not impose conditions, terms, obligations or restrictions and that such conditions,
terms, obligations or restrictions will not have the effect of delaying or preventing consummation of the WBD
Merger. For example, in July 2026, twelve states (California, Arizona, Colorado, Connecticut, Massachusetts,
-90-
Minnesota, Nevada, New Jersey, New Mexico, New York, Oregon and Washington) filed an antitrust action in the
U.S. District Court for the Northern District of California against Paramount and WBD relating to the WBD
Merger, seeking to block the WBD Merger, among other relief. On July 24, 2026, we entered into a stipulation
agreeing that the WBD Merger will not close, and we will not take any steps to integrate the operations of
Paramount with those of WBD, until the earlier of five days following the court’s ruling or June 1, 2027.
If in connection with any of the above or otherwise, WBD or Paramount is required to divest assets or businesses
or to agree to other conditions, obligations or restrictions on the conduct of its business, there can be no assurance
that we or WBD will be able to negotiate such divestitures or other measures expeditiously or on favorable terms
or that the governmental authorities will approve the terms of such divestitures or other measures. In addition, we
can provide no assurance that these conditions, terms, obligations or restrictions will not result in the abandonment
of the WBD Merger. If the conditions to completion of the WBD Merger are not satisfied or waived, we may be
unable to complete the WBD Merger in the time frame or manner currently anticipated or at all.
If the WBD Merger is not completed by September 30, 2026, we have agreed in the WBD Merger Agreement to
pay as merger consideration to WBD stockholders an additional amount in cash equal to $0.00277778 multiplied
by the number of calendar days elapsed after September 30, 2026, to and including the closing date (which, for the
avoidance of doubt, will not exceed $0.25 per 90 calendar day period). The anticipated closing of the WBD Merger
has been delayed as a result of the lawsuit described above, with the parties agreeing to postpone closing until the
earlier of five days following the court’s ruling or June 1, 2027.
Additionally, if the WBD Merger is not completed, our ongoing business may be adversely affected and we will be
subject to several risks or consequences, including:
- if the WBD Merger Agreement is terminated under certain circumstances, including where required regulatory
approvals have not been obtained or because a court order prevents the WBD Merger from closing on antitrust
grounds, we may be required to pay WBD a $7.0 billion Regulatory Termination Fee (as defined in the WBD
Merger Agreement), the payment of which would likely require us to issue additional equity pursuant to the
Subscription Agreements, with corresponding dilution to our existing stockholders;
- we will be required to pay certain costs relating to the WBD Merger, whether or not the WBD Merger is
consummated, such as significant fees and expenses relating to financial advisory, legal, accounting,
consulting or other advisory fees or expenses, employee-benefit or related expenses, regulatory filings or filing
and printing fees, none of which we would be able to recover;
- matters relating to the WBD Merger may require substantial commitments of time and resources by our
management or the expenditure of significant funds in the form of fees and expenses, which could otherwise
have been devoted to day-to-day operations or other opportunities that may have been beneficial to us;
- the commitments we have obtained to finance the WBD Merger, including a senior secured bridge term loan
facility, may require us to pay certain fees and expenses in connection with such commitments, and such fees
and expenses could be substantial;
- the ratings agencies could downgrade, or take other negative actions with respect to, our credit ratings or
ratings outlook, which could adversely affect our ability to obtain cost-effective financing;
- the price of our Class B Common Stock could decline significantly, including to the extent the current market
price reflects an assumption that the WBD Merger will be consummated;
-91-
- we would not realize the benefits expected from the WBD Merger, which could place us at a disadvantage in
competing with technology companies and others for content, creative talent and distribution;
- we would continue to operate on a standalone basis, without the cost savings, synergies and other benefits
expected from the WBD Merger, and as a result we may face greater challenges in executing our strategic and
financial plans, and be required to implement additional cost-reduction measures, including further reductions
in content and other spending, in order to achieve those plans; and
- declines in our linear television revenues are expected to persist, and the growth of our streaming business on a
standalone basis may be insufficient to offset them. See the risk factors included in our Annual Report on Form
10-K referred to above under “Risks Relating to Our Business and Industry.”
In addition, if the WBD Merger is not consummated, we may experience negative reactions from the financial
markets or from our employees, commercial partners, clients or customers. We could also be subject to litigation,
including litigation related to failure to consummate the WBD Merger or to enforce our obligations under the
WBD Merger Agreement. If the WBD Merger is not consummated, the risks described above may materially
adversely affect our business, financial condition, results of operations or stock price. For a description of the
circumstances under which the Regulatory Termination Fee is payable, see the WBD Merger Agreement.
Paramount and WBD must obtain certain regulatory approvals in order to consummate the WBD Merger; if
such approvals are not obtained or are obtained with conditions or if the WBD Merger is enjoined in connection
with legal or regulatory proceedings, the WBD Merger may be prevented or delayed or the anticipated benefits
of the WBD Merger could be reduced.
The Closing is conditioned upon, among other things, the clearance or approval by various regulatory authorities in
the United States and other jurisdictions and the absence of any orders enjoining the consummation of the WBD
Merger. As a condition to granting the necessary approvals or clearances, regulatory authorities may impose
conditions, terms, obligations or restrictions or require divestitures or place restrictions on our business after
consummation of the WBD Merger. If any such divestitures negatively impact our credit profile and credit ratings
as compared to the combined business if we did not have to undertake such divestitures, we may not be able to
obtain financing on as favorable terms as we otherwise anticipated, or at all. Any such requirements or restrictions
sought by regulatory authorities could negatively affect our business, financial condition or results of operations
following consummation of the WBD Merger. Any such requirements or restrictions may prevent or delay
consummation of the WBD Merger or may reduce the anticipated benefits of the WBD Merger, which could also
have a material adverse effect on our business, financial condition or results of operations.
The WBD Merger is subject to a number of Closing conditions and, if these conditions are not satisfied, the
WBD Merger Agreement may be terminated in accordance with its terms and the WBD Merger may not be
consummated. In addition, the parties have the right to terminate the WBD Merger Agreement under certain
circumstances, in which case the WBD Merger would not be consummated.
The WBD Merger is subject to a number of Closing conditions and, if these conditions are not satisfied or waived
(to the extent permitted by law), the WBD Merger may not be consummated. These conditions include: (i) the
expiration of certain mandatory waiting periods or receipt of certain other clearances or affirmative approvals of
certain governmental bodies, agencies or authorities and (ii) the absence of any law or order, issued by a court or
governmental entity of competent jurisdiction, restraining, enjoining, prohibiting or preventing the consummation
of the WBD Merger. Each of WBD’s and Paramount’s obligations to consummate the WBD Merger is also subject
to certain other conditions, including, among others, the compliance with pre-closing covenants by and the
accuracy of the representations and warranties of WBD (on the part of Paramount), on the one hand, and
Paramount and Merger Sub (as defined in the WBD Merger Agreement) (on the part of WBD), on the other hand
(in each case, subject to certain qualifications). Paramount’s obligation to consummate the WBD Merger is also
-92-
subject to (x) the absence of certain changes that have had, or would reasonably be expected to have, a material
adverse effect with respect to the Streaming and Studios segments of WBD and (y) WBD not having completed the
separation of its Streaming and Studios business from its Global Linear Networks business nor having declared or
made any dividend to WBD’s stockholders to effectuate such separation. These Closing conditions may not be
fulfilled and, accordingly, the WBD Merger may not be consummated.
Additionally, the WBD Merger Agreement may be terminated by either Paramount or WBD (i) by mutual written
consent, (ii) if any governmental entity of competent jurisdiction issues, enacts, enforces or enters any order
permanently enjoining or prohibiting the consummation of the WBD Merger, and such order becomes final and
non-appealable, or (iii) subject to certain limitations, if the Effective Time (as defined in the WBD Merger
Agreement) has not occurred on or before 11:59 p.m., Eastern time, on March 4, 2027 (the “End Date”), subject to
one automatic extension to June 4, 2027 if on such date all of the closing conditions, except those related to
regulatory approvals and governmental orders, have been satisfied or waived. In addition, (x) the WBD Merger
Agreement may be terminated by Paramount due to certain breaches by WBD of its representations, warranties and
covenants contained in the WBD Merger Agreement, subject to certain cure rights and (y) the WBD Merger
Agreement may be terminated by WBD due to certain breaches by Paramount of its representations, warranties and
covenants contained in the WBD Merger Agreement, subject to certain cure rights.
Litigation relating to the WBD Merger could prevent or further delay the Closing and/or result in the payment
of damages following the Closing.
In connection with the WBD Merger, we and WBD are subject to litigation and related proceedings, including
proceedings seeking to block or enjoin the WBD Merger or seeking monetary damages, and we may become
subject to additional litigation, demand letters, claims, enforcement actions or other proceedings relating to the
WBD Merger. See Note 14 to the consolidated financial statements appearing in Item 1 of Part I of this Quarterly
Report on Form 10-Q under the caption “Legal Matters—Litigation Relating to the WBD Merger,” and Part II,
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2026-04-01 to 2026-06-30 | $6.91bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2026-01-01 to 2026-06-30 | $14.26bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Selling, general and administrative | 3 months2026-04-01 to 2026-06-30 | $1.44bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2026-01-01 to 2026-06-30 | $2.85bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2026-04-01 to 2026-06-30 | $475.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2026-01-01 to 2026-06-30 | $1.09bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2026-04-01 to 2026-06-30 | $255.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2026-01-01 to 2026-06-30 | $493.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2026-04-01 to 2026-06-30 | $120.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2026-01-01 to 2026-06-30 | $275.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2026-04-01 to 2026-06-30 | $41.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2026-01-01 to 2026-06-30 | $209.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2026-04-01 to 2026-06-30 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2026-01-01 to 2026-06-30 | $0.19 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2026-04-01 to 2026-06-30 | $0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2026-01-01 to 2026-06-30 | $0.19 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2026-04-01 to 2026-06-30 | 1,120,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2026-01-01 to 2026-06-30 | 1,119,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2026-01-01 to 2026-06-30 | $504.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2026-01-01 to 2026-06-30 | $150.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2026-01-01 to 2026-06-30 | $117.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2026-06-30 | $1.63bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-06-30 | $11.02bn | us-gaap:AssetsCurrent |
| Total assets | At period end2026-06-30 | $44.41bn | us-gaap:Assets |
| Current liabilities | At period end2026-06-30 | $10.60bn | us-gaap:LiabilitiesCurrent |
| Short-term borrowings | At period end2026-06-30 | $0 | us-gaap:CommercialPaper |
| Shareholders' equity | At period end2026-06-30 | $11.77bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0002041610-26-000054. Last ingested by Listed: Nov 11, 2026, 03:58 ET. Listed shows no prices and gives no investment advice.